ATAI Life Sciences N.V. (NASDAQ: ATAI) Up Almost 0.51% In One Month, Long Term Looking Good

ATAI Life Sciences N.V. (NASDAQ:ATAI)’s traded shares stood at 2.95 million during the last session, with the company’s beta value hitting 0.95. At the close of trading, the stock’s price was $1.97, to imply an increase of 10.06% or $0.18 in intraday trading. The ATAI share’s 52-week high remains $2.39, putting it -21.32% down since that peak but still an impressive 48.22% since price per share fell to its 52-week low of $1.02. The company has a valuation of $327.04M, with an average of 1.34 million shares in intraday trading volume over the past 10 days and average of 1.51 million shares over the past 3 months.

ATAI Life Sciences N.V. (NASDAQ:ATAI) trade information

After registering a 10.06% upside in the last session, ATAI Life Sciences N.V. (ATAI) has traded red over the past five days. The stock hit a weekly high of 2.0400, jumping 10.06% in its intraday price action. The 5-day price performance for the stock is 17.96%, and 0.51% over 30 days. With these gigs, the year-to-date price performance is 39.72%. Short interest in ATAI Life Sciences N.V. (NASDAQ:ATAI) saw shorts transact 5.21 million shares and set a 3.34 days time to cover.

ATAI Life Sciences N.V. (ATAI) estimates and forecasts

Looking at statistics comparing ATAI Life Sciences N.V. share performance against respective industry, we note that the company has underperformed competitors. ATAI Life Sciences N.V. (ATAI) shares are 47.01% up over the last 6 months, with its year-to-date growth rate lower than industry average at -192.00% against 15.30%. Revenue is forecast to grow 23.80% this quarter before jumping 19.00% for the next one. The rating firms project that company’s revenue will shrink -4.50% compared to the previous financial year.

Earnings reports from the last fiscal year show that sales brought in $40k and $172k respectively in the corresponding quarters.

ATAI Dividends

ATAI Life Sciences N.V. has its next earnings report out between May 07 and May 14. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. ATAI Life Sciences N.V. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

ATAI Life Sciences N.V. (NASDAQ:ATAI)’s Major holders

ATAI Life Sciences N.V. insiders hold 10.05% of total outstanding shares, with institutional holders owning 28.02% of the shares at 31.15% float percentage. In total, 28.02% institutions holds shares in the company, led by Blackrock Inc.. As of Jun 29, 2023, the company held over 2.46 million shares (or 1.48% of shares), all amounting to roughly $4.23 million.

The next major institution holding the largest number of shares is Morgan Stanley with 2.11 million shares, or about 1.27% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $3.64 million.

We also have iShares NASDAQ Biotechnology ETF and SPDR (R) Ser Tr-SPDRï¿½ Kensho New Economies Composite ETF as the top two Mutual Funds with the largest holdings of the ATAI Life Sciences N.V. (ATAI) shares. Going by data provided on Aug 30, 2023, iShares NASDAQ Biotechnology ETF holds roughly 0.81 million shares. This is just over 0.49% of the total shares, with a market valuation of $1.23 million. Data from the same date shows that the other fund manager holds a little less at 0.66 million, or 0.40% of the shares, all valued at about 1.01 million.